On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO, as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect following the conclusion of the 2026 ASCO Annual Meeting.
Deb Schrag, MD, MPH, FASCO
Dr. Schrag, a gastrointestinal medical oncologist, is the George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) and Professor of Medicine at Weill Cornell Medical College. She is a population scientist and health services researcher who has worked to improve the quality, effectiveness, and experience of cancer care. Prior to her roles at MSKCC and Weill Cornell Medical College, Dr. Schrag served as Chief of the Division of Population Sciences at Dana-Farber Cancer Institute and as Professor of Medicine at Harvard Medical School.
Over her 2-decade career, Dr. Schrag has partnered with local, state, and federal agencies to design cancer control plans to advance population health. As a long-time ASCO member, Dr. Schrag has served in a variety of volunteer leadership roles, including as a member of the ASCO Board of Directors from 2008 to 2012. She chaired the Health Services Committee and worked on numerous other committees and task forces, including the Annual Meeting Scientific Program Committee, Quality and Practice Guidelines Committee, and the Joint Special Awards Selection Committee, and served as a mentor for ASCO’s Leadership Development Program.
“ASCO is at the forefront of cancer care and empowers the global oncology community by bringing us together to share knowledge, drive innovation and discovery, and join forces to improve outcomes for people with cancer everywhere,” said Dr. Schrag. “I thank ASCO’s members for trusting me with this important responsibility and look forward to partnering with them to advance the Society’s strategic plan and championing our shared values to accelerate progress.”
ASCO’s New Board Members
ASCO's Board of Directors comprises oncology leaders who are elected to positions reflecting various specialties within the oncology field. The following physicians will begin 4-year terms as members of ASCO's Board of Directors starting in June 2026.
Piyush Srivastava, MD, FASCO, has been elected to a Designated Community Oncologist seat. Dr. Srivastava is a gastrointestinal oncologist and palliative care physician at Kaiser Permanente with extensive leadership experience within ASCO. He has served as Chair of the Clinical Practice Committee, Government Relations Committee, and Clinician Well-Being Task Force, and currently chairs the Practice Quality Improvement Steering Group. He also serves on the Health Policy Committee and is a long-standing faculty member and coach for ASCO’s Quality Training Program. A graduate of ASCO’s Leadership Development Program, Dr. Srivastava now serves as a mentor and coach, reflecting his ongoing commitment to advancing quality and leadership in oncology care delivery.
C. S. Pramesh, MBBS, MS, FRCS, has been elected to a Designated International Oncologist seat. Dr. Pramesh is Director at Tata Memorial Hospital, Convener at the National Cancer Grid, and a Professor in the Division of Thoracic Surgical Oncology at Tata Memorial Centre in Mumbai, India. He is also a Visiting Professor in the Division of Cancer Studies, Faculty of Life Sciences and Medicine at King’s College London, and on the academic faculty at the Institute of Cancer Policy, King’s Health Partners Integrated Cancer Centre, United Kingdom. Dr. Pramesh has served as a member of various ASCO volunteer groups, including the International Affairs Committee, the Annual Meeting Scientific Program Committee, the Multidisciplinary Cancer Management Courses Working Group, and the International Education Steering Group. His work on reducing inequities in cancer control through the National Cancer Grid was recognized by the U.S. National Cancer Institute with the Rachel Pearline Global Cancer Research Humanitarian Award.
Karyn A. Goodman, MD, MS, FASTRO, FACR, FASCO, has been elected to the Designated Radiation Oncologist seat. Dr. Goodman is a Professor and Vice Chair of Radiation Oncology with a dual appointment as Professor of Medicine in the Division of Hematology and Oncology at the Icahn School of Medicine at Mount Sinai. She serves as the Associate Director of Clinical Research in the Tisch Cancer Institute. She has served as a member of various ASCO volunteer groups, including the Gastrointestinal (GI) Guideline Advisory Group, the GI Cancers Symposium Steering Committee, the Annual Meeting Scientific Program Committee, and the ASCO/AACR Methods in Clinical Cancer Research Workshop.
W. Kimryn Rathmell, MD, PhD, FASCO, has been elected to an Undesignated Member seat. Dr. Rathmell is the Chief Executive Officer of the Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She has served in a multitude of ASCO volunteer roles, including as Chair of the Nominating Committee and as a member of several groups, including the Annual Meeting Education Committee, Career Development Committee, and Ethics Committee. She is also a graduate of ASCO’s Leadership Development Program.
ASCO’s New Nominating Committee Members
Members of the Nominating Committee are tasked with developing a slate of candidates for elected ASCO positions. The following physicians will each serve a 3-year term on the ASCO Nominating Committee, beginning in June 2026.
Neeraj Agarwal, MD, FASCO, has been elected to an Undesignated Member seat. Dr. Agarwal is the Senior Director (also known as Associate Director) of the Cancer Center for Clinical Research; Professor in the Department of Internal Medicine (Medical Oncology); Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research; Director of Genitourinary Oncology in the Division of Medical Oncology; and Director of the Center of Investigational Therapeutics at the Huntsman Cancer Institute, University of Utah. He is a member of many ASCO volunteer committees, including the Patient Information Advisory Committee and the Meetings and Member Publications Editorial Board. Dr. Agarwal is also the current Editor-in-Chief of ASCO Daily News.
Ana I. Velázquez Mañana, MD, MSc, FASCO, has been elected to an Undesignated Member seat. Dr. Velázquez Mañana is an Assistant Professor of Clinical Medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) and a medical oncologist at UCSF Health and San Francisco General Hospital. She serves as Assistant Director of the Office of Education and Training of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Velázquez Mañana has served as Chair of the ASCO Trainee and Early Career Advisory Group and as a member of the Annual Meeting Scientific Program Committee, the Cancer Care Impact Committee, the Stage IV Non–Small Cell Lung Cancer Living Guideline Panel, the Clinical Trials Access Task Force, and the Social Media Working Group.
